Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when
given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with
multiple myeloma that has come back (relapsed) or has not responded to previous treatment
(refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein
called MDM2 that is needed for cell growth. Lenalidomide help shrink or slow the growth of
multiple myeloma. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving MDM2 Inhibitor KRT-232,
lenalidomide, carfilzomib, and dexamethasone together may work better in treating patients
with multiple myeloma.